Based on the Poxel SA stock forecast from 0 analysts, the average analyst target price for Poxel SA is not available over the next 12 months. Poxel SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Poxel SA is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Poxel SA’s stock price was EUR 0.394. Poxel SA’s stock price has changed by -27.97% over the past week, -30.14% over the past month and +5.77% over the last year.
No recent analyst target price found for Poxel SA
No recent average analyst rating found for Poxel SA
Company Overview Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France. Read Less
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tre...Read More
Frequently Asked Questions About Poxel SA (POXEL:PA) Stock
Stock Target Advisor's fundamental analysis for Poxel SA's stock is Bearish.
Unfortunately we do not have enough data on POXEL:PA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on POXEL:PA's stock to indicate what its average analyst target is.
POXEL:PA stock's Price/Earning ratio is 519.00.
Our analysis grades POXEL:PA stock's Price / Earning ratio at F. This means that POXEL:PA stock's Price/Earning ratio is above 90% of the stocks in the Biotechnology sector in the PA exchange.
Based on this POXEL:PA may be a overvalued for its sector.
The last closing price of POXEL:PA's stock was EUR 0.39.
The most recent market capitalization for POXEL:PA is EUR 0.03B.
Unfortunately we do not have enough analyst data on POXEL:PA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Poxel SA's stock.
As per our most recent records Poxel SA has 15 Employees.
Poxel SA's registered address is Immeuble Le Sunway, Lyon, France, 69007.
You can get more information about it from Poxel SA's website at https://www.poxelpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Poxel SA (POXEL:PA) Stock
Stock Target Advisor's fundamental analysis for Poxel SA's stock is Bearish.
Unfortunately we do not have enough data on POXEL:PA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on POXEL:PA's stock to indicate what its average analyst target is.
POXEL:PA stock's Price/Earning ratio is 519.00.
Our analysis grades POXEL:PA stock's Price / Earning ratio at F. This means that POXEL:PA stock's Price/Earning ratio is above 90% of the stocks in the Biotechnology sector in the PA exchange.
Based on this POXEL:PA may be a overvalued for its sector.
The last closing price of POXEL:PA's stock was EUR 0.39.
The most recent market capitalization for POXEL:PA is EUR 0.03B.
Unfortunately we do not have enough analyst data on POXEL:PA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Poxel SA's stock.
As per our most recent records Poxel SA has 15 Employees.
Poxel SA's registered address is Immeuble Le Sunway, Lyon, France, 69007.
You can get more information about it from Poxel SA's website at https://www.poxelpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for POXEL:PA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
